ReNeuron Group Limited
("ReNeuron" or the "Company")

Collaboration with Laverock Therapeutics to develop in-vivo gene therapy approaches

London, UK, 07 January 2026 – ReNeuron Group Limited, a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery systems, announces a collaboration with Laverock Therapeutics ('Laverock'), a company developing disease-responsive advanced therapies through its unique, programmable gene control technology, to develop in-vivo gene therapy approaches based on both company's platform technologies.

Under the collaboration Laverock will apply its miRNA gene silencing platform alongside ReNeuron's CustomEX™ exosome-based precision delivery technology, with the aim of validating in-vivo gene targeting. The collaboration will demonstrate the CustomEX™ platform's capability to precisely and functionally deliver a novel therapeutic modality that is currently difficult to achieve with conventional approaches. By validating the platform in this new context, the partnership is expected to unlock access to a broader spectrum of high-value therapeutic targets, including those historically considered undruggable, thereby creating new opportunities across multiple disease areas and significantly enhancing the long-term value of the CustomEX™ platform.

Laverock's platform recodes miRNAs to new therapeutic targets, with fully tuneable, allele specific control of gene expression, and high specificity. This allows a wide range of disease indications to be addressed, in particular those where gene dosage control is required. The project builds on Laverock's work to develop next-generation ex-vivo cell therapies - focused on T cell and Macrophages - allowing Laverock to maximise the impact of its platform.

ReNeuron's CustomEX™ platform comprises a portfolio of proprietary, stem cell-derived exosome producer cell lines that enable the consistent and scalable manufacture of exosomes with unique biological properties, including preferential miRNA loading and highly specific tissue and cellular targeting.

Randolph Corteling, Managing Director and Chief Scientific Officer of ReNeuron, commented: *"We are thrilled to announce our partnership with Laverock Therapeutics, which brings together their cutting-edge expertise in gene regulation with our advanced exosome-based delivery platform. By combining these complementary capabilities, we aim to accelerate the development of next generation gene therapies and bring transformative treatments to patients with critical unmet medical needs."*

David Venables, CEO of Laverock, said: *"We are delighted to announce this partnership with ReNeuron, utilising each company's proprietary platforms to develop in-vivo gene therapies. We believe this approach has broad application across a range of disease classes and provides a key solution to unlocking gene silencing in the CNS. We look forward to working with the team at ReNeuron and driving forward exosome delivered miRNA-based therapeutics for areas of high unmet need."*

Enquiries:

ReNeuron Group Limited **Via Walbrook PR**
Iain Ross, Chairman
Randolph Corteling, Managing Director & Chief Scientific Officer

Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 or Mob: +44 (0)7980 541 893



Laverock Therapeutics contact@laverocktx.com

About Laverock Therapeutics
Laverock Therapeutics is powering the development of disease-responsive advanced therapies through our unique, programmable gene control technology. Our innovative platform harnesses the cell's natural regulatory mechanisms to deliver programmable and tuneable gene control through recoded miRNAs. This enables the development of highly effective medicines with enhanced precision and improved safety profiles.

Utilising our platform technologies, we are working to develop the next-generation of advanced therapies, both through our own pipeline – targeting oncology and genetic medicine – and through partnerships.

Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised more than £20m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos Advisory, UK Innovation & Science Seed Fund, Tekfen Ventures and Norcliffe Capital.

For more information, please visit www.laverocktx.com and follow us on LinkedIn.

About ReNeuron
At ReNeuron, we are advancing precision medicine through the development of our CustomEX™ platform - a proprietary, stem cell-derived, exosome-based drug delivery platform with customisable cellular targeting capabilities for the delivery of complex therapeutic modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissue targets and payloads, leading to improved therapeutic outcomes and reduced off-target effects. ReNeuron's technology offers a delivery mechanism for a variety of payloads, such as siRNA, mRNA, proteins and small molecules.

In addition, our conditionally immortalised induced pluripotent stem cell (CI-iPSC) platform, allows the Company to make allogeneic cell lines of choice and has the potential to produce exosomes with discrete, tissue specific targeting capabilities.

Our leadership team and Board of Directors bring over 50 years of combined experience in the life sciences sector, having successfully guided multiple innovative platforms and medicines from development through to commercialisation.

For further information visit www.reneuron.com.